Native Hawaiians and other Pacific Islanders (NHPIs) across the country have experienced significant disparities because of the COVID-19 pandemic. The Pacific Alliance Against COVID-19 used a community-based participatory approach involving academic and community partners to expand sustainable COVID-19 testing capacity and mitigate the severe consequences among NHPI communities in Hawaii. We describe the approach of this one-year study, some of the results, and how the data are being used to inform next steps for the communities. Clinical Trials.gov identifier: NCT04766333. (. 2022;112(S9):S896-S899. https://doi.org/10.2105/AJPH.2022.306973).
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9707710 | PMC |
http://dx.doi.org/10.2105/AJPH.2022.306973 | DOI Listing |
Afr Health Sci
December 2023
Department of Medical Microbiology, Makerere University College of Health Sciences, Kampala, Uganda.
In 2013, Uganda introduced the PCV10 pneumococcal vaccine and it is given to children at 6, 10 and 14 weeks after birth. Carriage prevalence studies post PCV10-introduction are necessary for monitoring the impact of vaccination and trends in antibiotic resistance. Here, we studied carriage/antibiotic resistance of Streptococcus pneumoniae (pneumococcus), , and isolated from 194 children at the Mulago Assessment Centre clinic in Kampala-Uganda, 5 years post-PCV10 introduction.
View Article and Find Full Text PDFFront Immunol
August 2023
Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Eosinophils are important mediators of mucosal tissue homeostasis, anti-helminth responses, and allergy. Lung eosinophilia has previously been linked to aberrant Type 2-skewed T cell responses to respiratory viral infection and may also be a consequence of vaccine-associated enhanced respiratory disease (VAERD), particularly in the case of respiratory syncytial virus (RSV) and the formalin-inactivated RSV vaccine. We previously reported a dose-dependent recruitment of eosinophils to the lungs of mice vaccinated with alum-adjuvanted trivalent inactivated influenza vaccine (TIV) following a sublethal, vaccine-matched H1N1 (A/New Caledonia/20/1999; NC99) influenza challenge.
View Article and Find Full Text PDFAm J Public Health
November 2022
Ruben Juarez is with the Department of Economics and UHERO, University of Hawaii, Honolulu. Krit Phankitnirundorn, Rafael Peres, and Alika K. Maunakea are with the Department of Anatomy, Biochemistry and Physiology, John A. Burns School of Medicine, University of Hawaii, Honolulu. Aaron Ramirez is with the Waianae Coast Comprehensive Health Center, Waianae, HI. May Okihiro is with the Department of Pediatrics, John A. Burns School of Medicine, University of Hawaii, Honolulu.
Native Hawaiians and other Pacific Islanders (NHPIs) across the country have experienced significant disparities because of the COVID-19 pandemic. The Pacific Alliance Against COVID-19 used a community-based participatory approach involving academic and community partners to expand sustainable COVID-19 testing capacity and mitigate the severe consequences among NHPI communities in Hawaii. We describe the approach of this one-year study, some of the results, and how the data are being used to inform next steps for the communities.
View Article and Find Full Text PDFSci Adv
January 2022
Department of Pathology, National Institute of Infectious Diseases, 208-0011 Tokyo, Japan.
One safety concern during severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine development has been the vaccine-associated enhanced disease, which is characterized by eosinophilic immunopathology and T helper cell type 2 (T2)–biased immune responses with insufficient neutralizing antibodies. In this study, we established a lethal animal model using BALB/c mice and a mouse-passaged isolate (QHmusX) from a European lineage of SARS-CoV-2. The QHmusX strain induced acute respiratory illness, associated with diffuse alveolar damage and pulmonary edema, in T2-prone adult BALB/c mice, but not in young mice or T1-prone C57BL/6 mice.
View Article and Find Full Text PDFWorld J Clin Pediatr
September 2021
Department of Virology, School of Medicine, Bushehr University of Medical Sciences, Bushehr 7514633341, Iran.
Background: As long as oral poliovirus vaccine (OPV) is used, the potential risk for the emergence of vaccine-related polioviruses remains.
Case Summary: We report a case of Sabin-like type 1 poliovirus infection in an immunocompetent 17-mo-old child after receiving four scheduled doses of OPV. Somehow, the four doses did not confer full protection, possibly because of interference created by other enteroviruses.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!